Petros Pharmaceuticals In... (PTPI)
0.07
-0.00 (-4.11%)
At close: Mar 24, 2025, 3:59 PM
0.07
0.10%
After-hours: Mar 24, 2025, 07:58 PM EDT
-4.11% (1D)
| Bid | 0.07 |
| Market Cap | 2.03M |
| Revenue (ttm) | 12.25M |
| Net Income (ttm) | -32.25M |
| EPS (ttm) | -3.8 |
| PE Ratio (ttm) | -0.02 |
| Forward PE | -0.28 |
| Analyst | n/a |
| Ask | 0.07 |
| Volume | 4,492,019 |
| Avg. Volume (20D) | 7,392,439 |
| Open | 0.07 |
| Previous Close | 0.07 |
| Day's Range | 0.06 - 0.07 |
| 52-Week Range | 0.06 - 1.59 |
| Beta | 2.03 |
About PTPI
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vac...
Sector Healthcare
IPO Date Dec 2, 2020
Employees 21
Stock Exchange NASDAQ
Ticker Symbol PTPI
Website https://www.petrospharma.com
1 month ago
-53.48%
Petros Pharmaceuticals shares are trading lower af...
Unlock content with
Pro Subscription
2 months ago
+1.01%
Retros Pharmaceuticals shares are trading higher after the company announced it's in a position to lead the Rx-To-OTC switch market with its proprietary AI and quantum computing platform.
3 weeks ago · accessnewswire.com
Petros Pharmaceuticals' Proprietary Technology Demonstrates Positive Data in Pivotal StudyProprietary technology utilizing AI and big data integrations to enable Rx to OTC switch candidates across multiple indications NEW YORK, NY / ACCESS Newswire / February 25, 2025 / Petros Pharmaceutic...
